Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow-up of the PRIORITY study

Here are the Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow-up of the PRIORITY study journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Effect of spironolactone wash out temporary, what is a major side effect of spironolactone, side effects of gabapentin, side effect of spironolactone 25 mg tablet, effect of spironolactone wash out on albuminuria symptoms, side effects of lisinopril, most common side effect of spironolactone, effect of spironolactone wash out mtg, adverse effect of spironolactone, effect of spironolactone wash out shampoo.

Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow-up of the PRIORITY study

Aims: This study aimed to explore the effect of discontinuation of long-term spironolactone treatment on markers of kidney function in individuals with type 2 diabetes (T2D) at high risk of kidney disease enrolled in the Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria (PRIORITY) study. Materials and

Methods: An observational study following the nested randomised part of the PRIORITY study was conducted. A total of 115 individuals with T2D and normoalbuminuria but high risk for progression based on urinary proteomics, randomised to daily spironolactone (n = 50) or placebo (n = 65) for a median of 2.5 years, were re-examined approximately 6 weeks after the final visit in the PRIORITY study. Primary endpoint was relative change in geometric mean of urinary albumin-creatinine ratio (UACR) between the final visit in PRIORITY (baseline) and fol low-up. Secondary endpoints were change in estimated glomerular filtration rate (eGFR), systolic blood pressure (SBP) and serum potassium.

Results: No change in UACR was observed in neither the spironolactone (geometric mean change: 17%; 95% CI −12, 55; p = 0.28) nor the placebo (5%; 95% CI −13, 26; p = 0.63) group at follow-up. No difference in UACR between the groups was observed at follow-up (relative difference in geometric mean: 11%, 95% CI −26, 67; p = 0.60). For eGFR and SBP, an increase after discontinuation of spironolactone was observed, as well as for SBP after placebo discontinuation. Potassium levels were lower after discontinuation of spironolactone, but higher after placebo discontinuation (all p < 0.05). Conclusions: UACR did not change after discontinuation of long-term treatment with spironolactone. However, an increase in eGFR was observed supporting a haemodynamic effect of spironolactone in the kidneys. © 2024 John Wiley & Sons Ltd .

Authors : Wasehuus V.; Rotbain Curovic V.; Tofte N.; Lindhardt M.; Currie G.; Delles C.; Frimodt-Møller M.; Mischak H.; von der Leyen H.; Hansen T.W.; Kümler T.; Persson F.; Rossing P.; Stefansen R.; Campbell M.A.; Rossing P.; Mischak H.; Delles C.; von der Leyen H.; von der Leyen H.; Zimmermann S.; Rädisch B.; Hävemeier A.; Busmann A.; Wittkop U.; Neuhaus B.; Wölk H.; Ax-Smolarski R.; Zieglschmid V.; Bollweber E.; Mischak H.; Zürbig P.; Siwy J.; Durban A.; Raad J.; Schiemann M.; Prigge M.; Hansen T.W.; Wilson R.; Kean S.; Douglas E.; Surtees P.; Rossing P.; Frimodt-Møller M.; Tougaard N.H.; Eickhoff M.K.; Pilemann-Lyberg S.; Winther S.A.; Rosenlund S.; Hansen T.W.; von Scholten B.J.; Hansen C.S.; Zobel E.H.; Laursen J.C.; Theilade S.; Jelstrup L.; Juhl T.R.; Riis D.; Hermann J.; Lundgaard A.; Halkjær M.L.; Aabo L.; Lerche T.F.; Lajer M.; Navis G.; Bakker S.J.L.; Laverman G.D.; Gant C.; Yeung S.; Hagedoorn I.; Flynn J.; Delles C.; Currie G.; Petrie J.; B rooksbank K.; Galloway J.; Ruggenenti P.L.; Trillini M.; Parvanova A.; Aparicio M.C.; Iliev I.P.; Nones F.; Bue F.L.; Melacini D.; Cugini D.; Prandini S.; Lecchi V.; Yakymchuk S.; Gherardi G.; Villa A.; Villa D.; Gaspari F.; Cannata A.N.; Ferrari S.; Stucchi N.; Rychlik I.; Francova L.; Albrechtová Š.; Noutsou M.; Eldeik E.; Amanaki R.; Girman P.; Havrdova T.; Ortiz A.; Fernandez-Fernandez B.; Gonzalo M.Á.; Sanchez-Rodriguez J.; Vázquez C.; Sanz A.B.; Sanchez-Niño M.D.; Ramos A.M.; Beige J.; Dimos I.; Schmidt U.; Spasovski G.; Adamova K.; Gjorgovski T.; Selim G.; Stratrova S.S.; Stojceva-Taneva O.; Kooy A.; Schutten-Westerneng P.; Kleine A.; Wierbos B.; Huvers F.; Speeckaert M.; Lapauw B.; de Man E.; Dewettinck I.; Rokegem K.; Inion S.; Birkenfeld A.; Kreutzmann K.; Beulens J.W.J.; Rutters F.; Graaf C.B.-D.; Jong F.C.-D.; Entius J.; Nannings M.; van Steenderen S.; Göke R.; Petry F.; Kilic C.; Mogensen C.E.; Heerspink H.L.; Vlahou A.; Parving H.-H.; Vanholder R.; Schmieder R.; Jankowski J.; Schröder C.; Sabau R.

Source : John Wiley and Sons Inc